The quadrivalent influenza vaccine (split virion, inactivated) developed by the Wuhan Institute of Biological Products under China National Biotec Group Co Ltd (CNBG), a member company of China National Pharmaceutical Group Co Ltd (Sinopharm), had won the bid for the purchase order of the United Arab Emirates (UAE) this year, according to a notice sent on May 3 to Hayat Biotech, a joint venture of CNBG and UAE-owned technology firm G42.

This follows the earlier approval on Jan 3, when the vaccine received its drug registration certificate from the UAE’s Ministry of Health and Prevention.

The quadrivalent influenza vaccine is CNBG’s third vaccine approved and marketed in the UAE, following its inactivated COVID-19 vaccine and inactivated poliomyelitis vaccine.

This progress underscores the global recognition of CNBG's production, manufacturing and quality management for its vaccine products, which have met international benchmarks for quality, safety and efficacy.

The establishment of Hayat Biotech in 2020 marks the beginning of China-UAE cooperation in the biopharmaceutical sector. From the completion of the Hayat Biotech Life Sciences Park in 2022 to this recent procurement success, the partnership between the two countries has deepened, further enhancing Sinopharm's product presence in the UAE market and providing critical health protection for local people.

A file photo of the quadrivalent influenza vaccine (split virion, inactivated) developed by CNBG’s Wuhan Institute of Biological Products Co Ltd [Photo/sinopharm.com]

To date, nine vaccines from China have gained prequalification from the World Health Organization, with four of them developed and produced by CNBG.

CNBG has always prioritized the construction of a robust quality management system, aligning with the latest international regulations and guidelines. While meeting domestic vaccination needs, several CNBG vaccines, including those for Japanese encephalitis, chickenpox, poliomyelitis and influenza, have gained global approval for their stable quality. Currently, CNBG products are used in over 100 countries worldwide, following rigorous reviews and approvals.

Looking ahead, Sinopharm is committed to maintaining the highest standards of quality and safety. The group will continue to focus on technological innovation and contribute Chinese expertise to the global health landscape and the building of a worldwide health barrier.